JP2021534182A - 免疫原性組成物及びその使用 - Google Patents

免疫原性組成物及びその使用 Download PDF

Info

Publication number
JP2021534182A
JP2021534182A JP2021507889A JP2021507889A JP2021534182A JP 2021534182 A JP2021534182 A JP 2021534182A JP 2021507889 A JP2021507889 A JP 2021507889A JP 2021507889 A JP2021507889 A JP 2021507889A JP 2021534182 A JP2021534182 A JP 2021534182A
Authority
JP
Japan
Prior art keywords
self
antigen
replicating rna
rna molecule
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021507889A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534182A5 (cg-RX-API-DMAC7.html
Inventor
ジラルディン,シルヴィエ ベルトレート
クマール,アルン
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2021534182A publication Critical patent/JP2021534182A/ja
Publication of JP2021534182A5 publication Critical patent/JP2021534182A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2021507889A 2018-08-17 2019-08-16 免疫原性組成物及びその使用 Pending JP2021534182A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862719219P 2018-08-17 2018-08-17
US62/719,219 2018-08-17
PCT/EP2019/072052 WO2020035609A2 (en) 2018-08-17 2019-08-16 Immunogenic compositions and uses thereof

Publications (2)

Publication Number Publication Date
JP2021534182A true JP2021534182A (ja) 2021-12-09
JP2021534182A5 JP2021534182A5 (cg-RX-API-DMAC7.html) 2022-08-22

Family

ID=67766133

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021507889A Pending JP2021534182A (ja) 2018-08-17 2019-08-16 免疫原性組成物及びその使用

Country Status (7)

Country Link
US (2) US12083174B2 (cg-RX-API-DMAC7.html)
EP (1) EP3836963A2 (cg-RX-API-DMAC7.html)
JP (1) JP2021534182A (cg-RX-API-DMAC7.html)
CN (1) CN113164584A (cg-RX-API-DMAC7.html)
AU (1) AU2019321186B2 (cg-RX-API-DMAC7.html)
CA (1) CA3109165A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020035609A2 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3727444A1 (en) 2017-12-18 2020-10-28 Intervet International B.V. Swine influenza a virus vaccine
JP2023517644A (ja) 2020-03-09 2023-04-26 アークトゥラス・セラピューティクス・インコーポレイテッド コロナウイルスワクチン組成物及び方法
JP2023521662A (ja) 2020-04-03 2023-05-25 グリットストーン バイオ インコーポレイテッド 感染症抗原及びワクチン
IL298363A (en) * 2020-05-20 2023-01-01 Flagship Pioneering Innovations Vi Llc Immunogenic compositions and uses thereof
EP4168044A1 (en) 2020-06-19 2023-04-26 Intervet International B.V. Swine influenza a virus vaccine comprising two distinct rna replicon particles
US12178921B2 (en) 2020-08-14 2024-12-31 Arcturus Therapeutics, Inc. Method of lyophilizing lipid nanoparticles
MX2023004371A (es) 2020-10-14 2023-07-26 George Mason Res Foundation Inc Lípidos ionizables, y métodos de fabricación y uso de los mismos.
AU2021392077A1 (en) * 2020-12-02 2023-07-13 Seqirus Inc. Multicistronic rna vaccines and uses thereof
EP4313152A1 (en) * 2021-03-26 2024-02-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
US20240238404A1 (en) * 2021-05-19 2024-07-18 Daiichi Sankyo Company, Limited Influenza virus nucleic acid lipid particle vaccine
AU2022396547A1 (en) * 2021-11-29 2024-06-06 Replicate Bioscience, Inc. Methods of generating self-replicating rna molecules
WO2023213378A1 (en) * 2022-05-02 2023-11-09 BioNTech SE Replicon compositions and methods of using same for the treatment of diseases
US20240009296A1 (en) * 2022-07-10 2024-01-11 Pfizer Inc. Self-amplifying rna encoding an influenza virus antigen
TW202438672A (zh) * 2023-01-31 2024-10-01 美商亞克圖羅斯醫療公司 四價流感疫苗之方法及組成物
EP4661903A1 (en) * 2023-02-09 2025-12-17 Pfizer Inc. Nucleic acids and uses thereof
WO2024254461A2 (en) * 2023-06-07 2024-12-12 Nutech Ventures Methods and compositions for vaccine development and delivery
WO2024261648A1 (en) * 2023-06-19 2024-12-26 Seqirus Inc. Multivalent subtype influenza vaccine
CN117205309B (zh) * 2023-11-07 2024-02-02 今发制药(南京)有限公司 一种流感免疫原组合物和制备方法及其用途
WO2025210141A1 (en) * 2024-04-05 2025-10-09 Boehringer Ingelheim Vetmedica Gmbh Delivery system useful for topical administration of rna

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014522841A (ja) * 2011-07-06 2014-09-08 ノバルティス アーゲー カチオン性水中油型エマルジョン
WO2017123652A1 (en) * 2016-01-11 2017-07-20 Verndari, Inc. Microneedle compositions and methods of using same
JP2018035195A (ja) * 2013-01-10 2018-03-08 セキラス ユーケー リミテッドSeqirus UK Limited インフルエンザウイルス免疫原性組成物およびその使用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
PT1751289E (pt) 2004-05-18 2009-03-31 Alphavax Inc Vectores de alfavirais derivados da tc-83, partículas e métodos
EP2451475A2 (en) * 2009-07-06 2012-05-16 Novartis AG Self replicating rna molecules and uses thereof
WO2011076807A2 (en) 2009-12-23 2011-06-30 Novartis Ag Lipids, lipid compositions, and methods of using them
FI4005592T3 (fi) 2010-07-06 2023-01-13 Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille
CN103153284B (zh) 2010-07-06 2015-11-25 诺华股份有限公司 含有其pKa值有利于RNA递送的脂质的脂质体
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
CA2804591C (en) 2010-07-06 2019-01-22 Novartis Ag Cationic oil-in-water emulsions
JP5911870B2 (ja) 2010-08-31 2016-04-27 ノバルティス アーゲー 免疫原をコードするrnaの送達のためのpeg化リポソーム
RS63890B1 (sr) 2010-08-31 2023-02-28 Glaxosmithkline Biologicals Sa Mali lipozomi za isporuku rnk koja kodira imunogen
EP3542789A3 (en) 2010-08-31 2020-01-01 GlaxoSmithKline Biologicals SA Lipids suitable for liposomal delivery of protein-coding rna
RU2014104090A (ru) 2011-07-06 2015-08-20 Новартис Аг Липосомы с эффективным соотношением n:p для доставки молекул phk
US11058762B2 (en) * 2011-07-06 2021-07-13 Glaxosmithkline Biologicals Sa Immunogenic compositions and uses thereof
US9655845B2 (en) * 2011-07-06 2017-05-23 Glaxosmithkline Biologicals, S.A. Oil-in-water emulsions that contain nucleic acids
PT2750707T (pt) 2011-08-31 2019-01-23 Glaxosmithkline Biologicals Sa Lipossomas peguilados para distribuição de arn que codifica imunogénio
BR112014008694A2 (pt) * 2011-10-11 2017-06-20 Novartis Ag moléculas de ácido nucleico policistrônico recombinante
ES2887254T3 (es) 2013-03-08 2021-12-22 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
US10059655B2 (en) 2013-12-19 2018-08-28 Novartis Ag Lipids and lipid compositions for the delivery of active agents
US10426737B2 (en) 2013-12-19 2019-10-01 Novartis Ag Lipids and lipid compositions for the delivery of active agents
ES2969956T3 (es) 2014-09-05 2024-05-23 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
CN106822887A (zh) * 2017-01-26 2017-06-13 中国科学院微生物研究所 一种流感病毒四价亚单位疫苗及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014522841A (ja) * 2011-07-06 2014-09-08 ノバルティス アーゲー カチオン性水中油型エマルジョン
JP2018035195A (ja) * 2013-01-10 2018-03-08 セキラス ユーケー リミテッドSeqirus UK Limited インフルエンザウイルス免疫原性組成物およびその使用
WO2017123652A1 (en) * 2016-01-11 2017-07-20 Verndari, Inc. Microneedle compositions and methods of using same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MOLECULAR THERAPY, vol. 26, no. 2, JPN6023031251, 2018, pages 446 - 455, ISSN: 0005529457 *
VACCINE (AUTHOR MANUSCRIPT), vol. 27, no. 8, JPN6023031250, 2009, pages 1192 - 1200, ISSN: 0005529458 *

Also Published As

Publication number Publication date
AU2019321186B2 (en) 2024-05-23
US20250064916A1 (en) 2025-02-27
AU2019321186A1 (en) 2021-02-18
CA3109165A1 (en) 2020-02-20
US20210252133A1 (en) 2021-08-19
US12083174B2 (en) 2024-09-10
WO2020035609A2 (en) 2020-02-20
WO2020035609A3 (en) 2020-05-28
EP3836963A2 (en) 2021-06-23
CN113164584A (zh) 2021-07-23

Similar Documents

Publication Publication Date Title
US20250064916A1 (en) Immunogenic compositions and uses thereof
US12527856B2 (en) Artificial RNA molecules encoding a norovirus antigen and uses thereof
Elkashif et al. Adenoviral vector‐based platforms for developing effective vaccines to combat respiratory viral infections
US20220241398A1 (en) Lyssavirus antigen constructs
ES2869199T3 (es) Sistemas de expresión
JP2024503698A (ja) 変異型株ベースのコロナウイルスワクチン
US20240181037A1 (en) Immunogenic compositions
KR20250075664A (ko) 인플루엔자 바이러스 백신
EP3541416A1 (en) Zika viral antigen constructs
KR20230008707A (ko) 코로나바이러스 치료용 백신 조성물
CA3234653A1 (en) Influenza vaccines
WO2022137128A2 (en) Self-amplifying messenger rna
KR20250140103A (ko) 핵산 및 이의 용도
EP4701658A1 (en) Influenza virus vaccines
WO2025104620A1 (en) Immunogenic compositions against influenza

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220812

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220812

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230801

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241107

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250218